43LOW

AGN

ARGENICA FPO [AGN]
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Australia.
Healthcare · ASX Small Cap
$0.1650 +0.0%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical31
Catalyst54
Sentiment50
Fundamental44
Momentum19
Risk Gate42
Get alerts when AGN's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track AGN — Free

Active Signals

Bullish Signals

  • RSI is looking oversold — historically a spot where stocks tend to bounce
  • Stochastic is deep in oversold territory — bounce conditions forming
  • Volume surging at 2.3x normal while price falls — heavy selling pressure
  • Took a hit — down 17.5% over the last 5 days
  • Lagging the Small Ords index — relative strength of 0.84, underperforming its peers
  • Volatility is expanding fast — choppy price action, so buckle up
  • Low cash runway (2 quarters) - dilution risk
  • Revenue in sharp decline (-78%)
  • Near 52-week low (0% of range)
  • Small-cap ($20-100M)
  • Sentiment is mixed — no strong consensus either way
  • This one has been in freefall — down 73% over the past year
  • Altman Z-Score distress zone (0.57 < 1.81, low-confidence approx)
  • RBA hiking (-3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Revenue declining at -78% — the top line is shrinking
  • The bigger volume days are the down days — volume-weighted momentum is negative (-3.24%/day)
  • Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about AGN
"What's driving AGN's score?" "How does AGN compare to peers?" "Key risks for AGN?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

LOW Presentations at European Stroke Organisation Conference
LOW Investor Presentation - Euroz Hartleys Healthcare Conference
NONE Argenica Receives $3.97m R&D Tax Incentive Cash Rebate
NONE Half Yearly Report and Accounts
NONE Successful Applicaton for EMA Paediatric Waiver

Recent ASX Announcements

2026-03-25 Presentations at European Stroke Organisation Conference PRICE SENSITIVE
2026-03-16 Argenica Receives $3.97m R&D Tax Incentive Cash Rebate PRICE SENSITIVE
2026-02-10 Half Yearly Report and Accounts PRICE SENSITIVE
2026-02-04 Investor Presentation - Euroz Hartleys Healthcare Conference
2026-02-01 Successful Applicaton for EMA Paediatric Waiver PRICE SENSITIVE

Key Metrics

$21.2M
Market Cap
168K
Avg Volume
2.3x
Vol Ratio
$0.17 — $0.85
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-117.8%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 72%
LLeader vs LaggardlaggardRS: -10
IInstitutional SponsorshipweakInst: 1%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #79 of 117 · Sector avg: 46

View all Healthcare signals →
Related Tickers
ATX 59PNV 56IMM 55EYE 55AHC 55
Compare:AGN vs ATXAGN vs PNVAGN vs IMM
Scout Pro — Deeper Analysis for AGN
Try Pro free for 30 days
Share this analysis

Track AGN and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required